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Acute Effects of Three Different Meal Patterns on
Postprandial Metabolism in Older Individuals with a Risk
Phenotype for Cardiometabolic Diseases: A Randomized
Controlled Crossover Trial
Yannik B. Schönknecht, Silke Crommen, Birgit Stoffel-Wagner, Martin Coenen,
Rolf Fimmers, Jens J. Holst, Marie-Christine Simon, Peter Stehle, and Sarah Egert*
Scope: The aim of this study is to investigate acute postprandial responses to
intake of meals typical for Mediterranean and Western diets.
Methods: In a randomized crossover design, overweight and obese
participants with a risk phenotype for cardiometabolic diseases consumed
three different isoenergetic meals: Western diet-like high-fat (WDHF), Western
diet-like high-carbohydrate (WDHC), and Mediterranean diet (MED) meal.
Blood samples are collected at fasting and 1, 2, 3, 4, 5 h postprandially and
analyzed for parameters of lipid and glucose metabolism, inflammation,
oxidation, and antioxidant status.
Results: Compared to MED and WDHF meals, intake of a WDHC meal
results in prolonged and elevated increases in glucose and insulin. Elevations
for triglycerides are enhanced after the WDHF meal compared to the MED
and the WDHC meal. Glucagon-like peptide-1 and interleukin-6 increase
postprandially without meal differences. Apart from vitamin C showing an
increase after the MED meal and a decrease after WDHF and WDHC meals,
antioxidant markers decrease postprandially without meal differences. Plasma
interleukin-1𝜷 is not affected by meal intake.
Conclusions: Energy-rich meals induce hyperglycemia, hyperlipemia, an
inflammatory response, and a decrease in antioxidant markers. A meal typical
for the Mediterranean diet results in favorable effects on glycemic,
insulinemic, and lipemic responses.
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1. Introduction
Nowadays, innovative nutrition research
has undergone a considerable change
of concept: Instead of focusing on the
association between single nutrient in-
take and disease, scientific interest now
targets the role of complex dietary pat-
terns as risk factors in the development
of chronic diseases throughout the life
cycle.[1,2] Dietary patterns that are typ-
ically encountered in Western societies
are characterized by a high consump-
tion of energy-dense processed foods and
ready-to-eat meals and of animal protein,
saturated fatty acids (SFA), and added
sugar and sodium.[3] Adherence to West-
ern dietary patterns is associated with a
physically inactive lifestyle and is com-
monly associated with the development
of obesity and metabolic risk factors.[4]
By contrast, so-called “health promoting”
dietary patterns, including the Mediter-
ranean diet, are characterized by native
or only minimally processed foods, fruit,
vegetables and vegetable oils, with few
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highly processed foods or sugary beverages. Such dietary patterns
are also naturally lower in sodium, trans fatty acids and SFA, re-
fined carbohydrates and added sugars; they are also higher in
unsaturated fatty acids, dietary fiber, antioxidants, minerals, and
phytochemicals and are more satiating than a typical Western
diet.[1,2] Therefore, adherence to a Mediterranean-style diet is as-
sociated with reduced risk of cardiometabolic and other chronic
diseases.[5,6]
Characteristic for the modern Western eating behavior is a
frequent excessive intake of food. As a result, many individu-
als spend the majority of their waking hours in the postpran-
dial state and experience exaggerated and prolonged postpran-
dial metabolic (lipemia, glycemia/insulinemia), oxidative and
immune imbalances, a phenomenon termed “postprandial ox-
idative stress.”[7,8] This prolonged pro-oxidative state is accompa-
nied by low-grade inflammation and impaired endothelial func-
tion and can promote cellular dysfunction and cardiovascular dis-
ease (CVD).[7,9] There is growing evidence that exaggerated and
prolonged postprandial oxidative stress contributes to atheroscle-
rosis, CVD, and other chronic diseases.[10,11]
Earlier human intervention studies conducted to primarily
evaluate postprandial responses supplied single carbohydrates,
proteins, or lipids, or have used combinations of a standardized
high-fat meal plus a functional ingredient (e.g., a flavonoid or a
specific food).[7,9,12,13] These studies indicate that the energy con-
tent of themeal, as well as the content of high-glycemic index car-
bohydrates and SFA, are important modulators of the postpran-
dial immune response. By contrast, dietary fiber, unsaturated
fatty acids, and anti-oxidative compounds may suppress post-
prandial inflammation. To the best of our knowledge, no previ-
ous study has examined the effects of different dietary patterns on
postprandial events. Therefore, the aim of the present random-
ized crossover trial was to systematically investigate the postpran-
dial metabolic responses to three different dietary patterns. We
hypothesized that postprandial lipemic, glycemic, and inflamma-
tory responses are lower after consuming a Mediterranean-type
meal than after meals typical of a Western dietary pattern. Se-
lected participants were older (age range of 60–80 years), over-
weight, or obese adults with a cluster of metabolic syndrome
traits, because this group has higher postprandial lipemia than
young, normal-weight, and metabolically healthy adults.[14,15] In
addition, overweight/obesity is associated with obesity-induced
inflammation, so-called metaflammation.[8,10] We assumed that
postprandial inflammatory responses can be particularly evident
in individuals with this phenotype.
2. Experimental Section
2.1. Participants
Participants were recruited in Bonn, Germany, via advertise-
ments in local newspapers, public postings and flyers. Of 446
individuals who expressed an interest, 127 aged 60–80 years
with a BMI of 27–34,9 kg m−2, attended screening, which in-
cluded physical assessments (body height and weight, resting
blood pressure [BP], heart rate, and waist and hip circumfer-
ence), blood analyses in fasting blood samples (fasting serum
creatinine, urea, sodium, potassium, bilirubin, uric acid, gamma-
glutamyl transferase, alanine transaminase, aspartate transami-
nase, hepatic lipase, blood counts, serum lipids and lipoproteins,
glucose, insulin, HbA1c, and high-sensitivity C-reactive protein
[CRP]), medical history, and a dietary questionnaire.
Individuals were included if they had the following cluster of
risk factors for cardiometabolic diseases: 1) overweight or obe-
sity stage 1 (BMI of 27–34,9 kg m−2); 2) visceral fat distribu-
tion (waist circumference ≥ 94 cm for men and ≥ 80 cm for
women)[16]; 3) pre-hypertension (systolic BP ≥ 120–139 mmHg
and/or diastolic BP ≥ 80–89 mmHg) or hypertension (systolic
BP ≥ 140–159 mmHg and/or diastolic BP ≥ 90–99 mmHg)[17];
and 4) at least one of the following criteria: impaired glucose tol-
erance (fasting plasma glucose ≥ 5.55 mmol L−1)[16] and/or dys-
lipidemia (fasting serum triglycerides ≥ 1.7 mmol L−1 or serum
HDL cholesterol < 1.0 mmol L−1 for men and < 1.3 mmol L−1
for women)[16] and/or a pro-inflammatory state (high-sensitivity
CRP ≥ 2.0 mg dL−1).[18] Besides the pro-inflammatory state,
the inclusion criteria are based on the diagnostic criteria of the
metabolic syndrome.[16]
The main exclusion criteria were smoking, insulin-treated dia-
betes mellitus, long-term intake of dietary supplements, inflam-
matory disease, disease of the liver, kidney, or gastrointestinal
tract, a history of cardiovascular events, abnormal thyroid func-
tion, cancer, recent major surgery or illness, substance or alcohol
abuse, participation in a weight loss program, andmalabsorption
syndromes.
The protocol was explained in detail to all participants, who
provided written informed consent at the beginning of the
study. The study protocol was approved by the Ethics Commit-
tee of the Medical Faculty of the Rheinische Friedrich-Wilhelms-
Universität Bonn, Germany, and the study was conducted in ac-
cordance with the declaration of Helsinki. The trial was regis-
tered at http://www.germanctr.de and http://www.drks.de under
identifier DRKS00009861.
The participants were instructed to maintain their usual diet,
level of physical activity, lifestyle, and body weight throughout
the study period. The use of antihypertensive medication, such
as angiotensin II receptor blockers and beta-blockers, statins,
biguanides (metformin), and thyroid medication, were no exclu-
sion criteria. Participants requiring antihypertensive agents (n =
29), lipid-lowering drugs (n = 16), metformin (n = 3), or thyroid
therapy (n= 15) were instructed to continue their usual regimen.
2.2. Study Design
This study was a randomized, dietary-controlled crossover trial.
Each participant took part in three 5-h meal tests from morn-
ing until afternoon. Study days were separated by 2-week wash-
out periods. The participants were assigned to the three different
test meals by block randomization procedure via computer-
generated randomization tables (Microsoft Excel 2010, Microsoft
Corporation, RedmondWA,USA). Thereby the order of testmeal
consumption was randomized. Ten participants were allocated
equally to each of six orders.
All participants were instructed to abstain from alcohol on the
day before the test and to refrain from intensive physical activ-
ity for 12 h prior to the test. In addition, they were instructed to
standardize theirmeal intake on the previous evening. Tests were
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Table 1. Energy content and nutrient composition of the three test meals.
WDHF
meal
WDHC
meal
MED
meal
Energy [kJ] 4230 4241 4238
Energy density [kJ g−1] 7.2 9.8 5.6
Carbohydrates [g] 94 145 133
Carbohydrates [EN %] 37 58 53
Mono- and
disaccharides [g]
45 87 51
Polysaccharides [g] 47 57 79
Ratio of
polysaccharides to
mono- and
disaccharides
1.0 1.5 0.6
Dietary fiber [g] 4 5 14
Protein [g] 26 26 26
Protein [EN %] 10 10 10
Total fat [g] 59 34 40
Total fat [EN %] 53 31 36
SFA [g] 32 19 6
MUFA [g] 20 11 24
n-3 PUFA [g] 1 0 2
n-6 PUFA [g] 3 2 7
𝛽-carotene [mg] 0.2 2.3 4.8
Retinol [mg RE] 365 522 832
Vitamin E [mg TE] 2.3 2.9 10.8
Vitamin C [mg] 9 16 102
EN%, energy percent; MED, Mediterranean diet-like meal; MUFA, monounsaturated
fatty acids; PUFA, polyunsaturated fatty acids; RE, retinol equivalent; SFA, saturated
fatty acids; TE, tocopherol equivalent; WDHC, Western diet-like high-carbohydrate
meal; WDHF Western diet-like high-fat meal.
then conducted in themorning after a 10–12 h overnight fast. Ve-
nous blood sampling was performed prior to the meal (0 h) and
at 1, 2, 3, 4, and 5 h after finishing themeal. Participants stayed at
the study site (Department of Nutritional Physiology, University
of Bonn) the entire time for 5 h. Participants were asked to limit
movement during the test meal period, remain seated when pos-
sible and were encouraged to read or to play card games during
the study period. No foods other than the test meals were con-
sumed over the test period and mineral water was provided.
2.3. Meal Composition
Three different isoenergetic (4200 kJ) and isonitrogenmeals were
designed to represent different dietary patterns: a Western diet-
like high-fat (WDHF) meal, rich in total fat, SFA, and animal
protein; a Western diet-like high-carbohydrate (WDHC) meal,
rich in refined carbohydrates; and a Mediterranean diet (MED)
meal, rich in unsaturated fatty acids, dietary fiber, and antiox-
idative compounds. The nutrient composition of the meals is
summarized in Table 1. The meals were calculated using the
computer-based nutrient calculation program EBISpro, based
on the German Nutrient Database Bundeslebensmittelschlüssel,
version 3.01 (Max Rubner-Institut, Karlsruhe, Germany). The
WDHF meal consisted of a bread roll, butter, cold cuts of meat,
cream yoghurt, an egg, and a croissant. The main components
of the WDHC meal were a bread roll, butter, hazelnut spread
(Nutella), strawberry jam, and toast. The MED meal consisted of
ciabatta, olive oil, cured salmon, fruit and vegetables.
The test meals were freshly prepared on the morning of each
test day in a dedicated kitchen of the Agricultural Faculty of the
University of Bonn, Germany, by study personnel in accordance
with a standardized protocol, which included the weighing of
each food component to the nearest gram. Meals were served
as breakfast. In addition to the meal, the participants drank one
glass of water. The participants were required to complete the
meal within 20 min under observation by a member of the labo-
ratory staff.
2.4. Measurements
2.4.1. Anthropometrics
Body height and body weight were determined to the nearest
0.1 cm and 0.1 kg, respectively, using a scale with an integrated
stadiometer (seca 704, Seca, Hamburg, Germany). Waist circum-
ference was measured midway between the lowest rib and the il-
iac crest, while the participant was at minimal respiration. Hip
circumference was measured at the height of trochanters ma-
jores. Both measurements were performed in duplicate in an up-
right position and to the nearest 0.1 cm. Body composition (fat
mass [FM] and fat-free mass [FFM]) was determined by bioelec-
trical impedance analyses (Nutrigard-M, Multi Frequency Phase-
Sensitive Bioelectrical Impedance Analyzer, Data Input). FFM
was calculated according to themethod published by Sun et al.[19]
FM was calculated by subtracting FFM from body weight.
2.4.2. Office BP and Heart Rate
Office BP and heart rate were measured with an automatic
BP measurement device (Boso Carat Professional, Bosch +
Sohn GmbH, Jungingen, Germany) under standardized condi-
tions according to the recommendations of the American Heart
Association.[20,21]
2.4.3. Blood Sample Processing and Analysis
Venous blood samples were taken via cannula (Vasofix Safety, B.
Braun Melsungen AG) and drawn into tubes containing EDTA,
lithium heparin, fluoride, or a coagulation activator (Sarstedt).
Plasma and serum were obtained by centrifugation at 3000 g for
15 min at 8 °C. Plasma/serum aliquots were immediately frozen
in cryovials and stored at −80 °C until analysis. All analyses were
performed in a blinded manner.
2.4.4. Plasma Glucose, Serum Insulin, Plasma Glucagon-Like
Peptide-1 (GLP-1), and Lipids
Glucose concentration of the plasma samples was assessed via
bichromatic endpoint measurement with a Dimension Vista
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1500 analyzer (Siemens Healthcare Diagnostics, Erlangen, Ger-
many). Serum insulin concentrations were determined using
chemiluminescent-immunometric assay with an Immulite 2000
analyzer (Siemens Healthcare Diagnostics). The sum of the
plasma concentrations of GLP-1 (7-36) amide and GLP-1 (9-36)
amide was measured as previously described.[22]
The serum total cholesterol concentration was measured us-
ing polychromatic endpoint measurement, while serum concen-
trations of HDL cholesterol, LDL cholesterol, and serum tria-
cylglycerols were assessed using endpoint measurement with a
Dimension Vista 1500 analyzer (Siemens Healthcare Diagnos-
tics). Serum concentrations of non-esterified fatty acids (NEFA)
were determined with a commercially available colorimetric en-
zyme assay (Wako Chemicals GmbH).
2.4.5. Biomarkers of Inflammation and Endothelial Activation
Plasma concentrations of interleukin-1𝛽 (IL-1𝛽) and interleukin-
6 (IL-6), soluble adhesion molecules E-selectin (sE-selectin), in-
tercellular adhesion molecule-1 (sICAM-1), and vascular cell ad-
hesion molecule-1 (sVCAM-1) were analyzed in duplicate using
commercially available ELISA (R&DSystems) in accordance with
the manufacturer’s instructions.
2.4.6. Biomarkers of Oxidation and Antioxidant State
Plasma oxidized LDL (oxLDL) was determined in duplicate using
commercially available enzyme-linked immunoassay kits (Im-
mundiagnostik, Bensheim, Germany) according to the manu-
facturer’s instructions. Plasma concentrations of 𝛼-tocopherol,
retinol, and 𝛽-carotene were determined via HPLC as described
previously.[23] The total antioxidant capacity of plasma sam-
ples was measured using the trolox equivalent capacity (TEAC)
method.[24] For vitamin C analysis, metaphosphoric acid was
added to the plasma samples to increase stability. After centrifu-
gation, the supernatant was poured into vials and analyzed using
HPLC with UV detection.
2.4.7. Self-Reported Dietary Intake of Energy and Nutrients
For the purpose of standardization, the participants were in-
structed by two qualified nutritionists to complete a 3-day food
diary on the days prior to each study visit, in order tomonitor and
identify possible variations in total intake of energy andmacronu-
trients. The dietary records by analyzed by using the computer-
based nutrient calculation program EBISpro.
2.5. Statistical Analyses
Serum triglycerides were defined as primary outcome. Based on
a sample size of n = 54 participants, one would be able to de-
tect a difference within a variable in the size of 40% of the stan-
dard deviation of the difference with a power of 80% holding for
a two-side t-test at a level of 5%. Assuming a standard deviation
of 0.5 mmol L−1, we were able to detect a difference of 0.2 mmol
L−1 in serum triglycerides between two of the diets. We increased
sample size to n = 60 with respect to a drop-out rate of 10%.
Statistical analyses were performed using the IBM SPSS sta-
tistical software package (version 23, IBM, Armonk, NY, USA).
To identify potential differences in total energy and macronutri-
ent intake (as recorded in the 3-day food diaries) on the days prior
testing, the data were compared using a 1-factor ANOVA. Partici-
pants’ baseline characteristics at screening were analyzed for sex
differences by unpaired Student’s t-test orMann–WhitneyU-test.
Variables were checked for differences prior to test meal intake
with the use of a mixed model analysis.
Linear mixed models were used to test for the effects of time,
test meal and any correlation with postprandial outcomes. Fast-
ing values were included as covariates. Participants were in-
cluded as random factors. When there was no evidence of the
presence of interaction (p> 0.05), mixedmodel calculations were
repeated without an interaction term. When there was evidence
for significant interaction terms, data were analyzed by each time
point separately performing linear mixed model calculations as
post hoc analyses.
Residuals obtained from the mixed model were inspected for
normality to control for the fit of the statistical model. Logarith-
mic transformation was applied before analysis if the residuals
were not normally distributed, which was given for glucose, in-
sulin, IL-1𝛽, IL-6, and sVCAM-1.
Summary measurements for postprandial response were cal-
culated as AUC. The incremental AUC (iAUC) was calculated for
the concentration of all postprandial study variables. Calculations
were performed as reported previously.[25] Data are expressed as
mean ± SEM; given p-values are two-sided.
3. Results
3.1. Baseline Characteristics
Sixty participants (34 male, 26 female) were considered eligible
and enrolled in the study; all participants completed the entire
postprandial study and were included in the analysis. Participant
flow from initial screening to final analysis is shown in Figure 1.
Baseline characteristics are summarized in Table 2. Based on
BMI, all participants were overweight or obese (43% and 57%,
respectively), had elevated BP or hypertension (n = 11 and 49,
respectively), and had visceral fat distribution. Significant differ-
ences were seen between the male and the female groups in
terms of body weight, height, waist circumference, percentage
body FM, heart rate, total cholesterol, HDL cholesterol, and CRP
(Table 2). Significantly lower body weight, height and waist cir-
cumference and higher percentage body FM, heart rate, total
cholesterol, HDL cholesterol, and CRP was evident in women
compared with men (Table 2).
3.2. Self-Reported Dietary Intake of Energy and Nutrients
All participants maintained their usual dietary pattern through-
out the study. Nutrient intake remained unchanged and energy
intake also did not differ prior to any study visit (data not
shown).
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Figure 1. Flow diagram of participants.
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Table 2. Participants characteristics and blood parameters at screening.
Total Male Female p-value
[n = 60] [n = 34] [n = 26] [Female vs male]
Age [years] 69.8 ± 5.3 70.2 ± 5.2 69.3 ± 5.6 0.556
Body weight [kg] 88.8 ± 10.3 93.5 ± 8.5 82.7 ± 9.3 <0.001
Height [m] 1.70 ± 0.80 1.75 ± 0.05 1.62 ± 0.06 <0.001
BMI [kg m−2] 30.9 ± 3.1 30.5 ± 2.9 31.4 ± 3.4 0.318
Waist circumference [cm] 105.6 ± 8.3 108.9 ± 7.7 101.4 ± 7.7 <0.001
Waist-to-height ratio 0.62 ± 0.05 0.62 ± 0.05 0.63 ± 0.05 0.823
Fat mass [%] 33.9 ± 7.4 28.3 ± 4.0 41.2 ± 3.3 <0.001
Systolic BP [mmHg] 148 ± 16 147 ± 13 148 ± 19 0.881
Diastolic BP [mmHg] 89 ± 9 87 ± 9 92 ± 9 0.039
Pulse [min−1] 65 ± 11 62 ± 10 68 ± 11 0.021
Plasma glucose [mmol L−1] 5.5 ± 1.0 5.4 ± 1.0 5.5 ± 1.0 0.976
Serum insulin [pmol L−1] 82.7 ± 35.2 83.1 ± 35.2 82.1 ± 35.9 0.913
Serum triglycerides [mmol L−1] 1.91 ± 0.85 1.96 ± 0.92 1.85 ± 0.75 0.618
Serum total cholesterol [mmol L−1] 5.33 ± 0.95 5.08 ± 1.02 5.66 ± 0.76 0.014
Serum HDL cholesterol [mmol L−1] 1.43 ± 0.37 1.32 ± 0.29 1.57 ± 0.42 0.014
Serum LDL cholesterol [mmol L−1] 3.31 ± 0.80 3.17 ± 0.85 3.48 ± 0.71 0.128
Serum hs-CRP [mg L−1] 4.6 ± 6.9 2.6 ± 3.8 7.2 ± 9.1 <0.001
BP, blood pressure; hs-CRP, high-sensitivity C-reactive protein; All blood parameters were measured in fasting samples. Values are shown as mean ± SD; comparisons were
performed using an unpaired Student’s t-test or a Mann–Whitney U-test.
3.3. Plasma Glucose, Serum Insulin, and Plasma GLP-1
Significant concentration differences in plasma glucose and
serum insulin were seen at certain time points after meal
intake, indicated by time × meal interactions for plasma
glucose (p = 0.008) and serum insulin (p = 0.033) after
meal intake. Postprandial values increased significantly from
baseline (p < 0.001 for glucose and insulin) and were signifi-
cantly influenced by themeal (p= 0.013 for glucose; p< 0.001 for
insulin; Figure 2A,B). AfterWDHCmeal intake, glucose increase
persisted significantly longer and insulin values were signifi-
cantly higher throughout the postprandial period. IAUC values
differed significantly between themeals and the highest glycemic
response and an insulinemic response was seen after WDHC
meal intake (p = 0.002 for glucose; p < 0.001 for insulin; Table 3).
Plasma GLP-1 increased significantly over time (p < 0.001;
Figure 2E). No differences were seen in GLP-1 concentrations
(p = 0.706) as well as in iAUC between the meals (p = 0.978).
3.4. Serum Lipids, Lipoproteins, and NEFA
Serum triglycerides showed a significant time ×meal interaction
(p = 0.005; Figure 2D). There was a significant time-dependent
increase in serum triglycerides from baseline to all time points,
reaching a maximum concentration after 3 h and elevated values
after 5 h (p < 0.001). At 2–5 h, the WDHF meal induced signifi-
cantly higher values than the othermeals (significant meal effect;
p < 0.001), which was also reflected as a significant difference in
iAUC (p< 0.001; Table 3). Analyses revealed no significant time×
meal interaction for lipoproteins, but a significant decrease over
time (LDL cholesterol: p < 0.001; HDL cholesterol: p < 0.001; to-
tal cholesterol: p < 0.001) as well as a significant influence of the
meal for HDL (p < 0.001) and total cholesterol (p = 0.007), but
not for LDL cholesterol (p = 0.053). There was no detectable dif-
ference in AUC values for LDL, HDL, and total cholesterol (Table
3).
Meals induced a decrease in NEFA below baseline values in
the early postprandial phase. Values subsequently increased but
did not return to baseline values within the measurement period
(Figure 2C). At 2–5 h, NEFA concentrations were significantly
higher after theWDHFmeal than after the other meals. This was
identified as a significant time × meal interaction (p < 0.001), a
significant meal effect (p < 0.001), and a significant time effect
(p < 0.001).
3.5. Plasma Soluble Adhesion Molecules, IL-1𝜷, and IL-6
Soluble adhesion molecules (sICAM-1, sVCAM-1, and sE-
selectin) showed no significant time × meal interaction (Fig-
ure 3C,D). Meal intake induced no changes in sICAM-1 (time
effect, p = 0.077; meal effect, p = 0.131). Significant decreases
in sE-selectin and sVCAM-1 levels were seen over time (p< 0.001
and p = 0.002, respectively). A significant influence of the meal
was also detected for sE-selectin (p = 0.002). Adhesion molecule
AUC values were not affected by the meal (Table 3).
IL-1𝛽 was not affected by meal intake (p = 0.802), time (p =
0.104), or the interaction of these parameters (p = 0.537; Fig-
ure 3A). Plasma IL-6 significantly increased over time (p < 0.001;
Figure 3B). No differences were seen in IL-6 concentrations (p =
0.065) nor in iAUC between the meals (p = 0.488).
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Figure 2. Fasting and postprandial concentrations of A) plasma glucose, B) serum insulin, C) serum NEFA, D) serum triglycerides and E) plasma GLP-1
in participants of high risk of CVD. Data are presented as mean ± SEM. GLP-1, glucagon-like peptide-1; MED, Mediterranean diet-like meal; NEFA,
non-esterified fatty acids; WDHF, Western diet-like high-fat meal; WDHC, Western diet-like high-carbohydrate meal. ●●●p < 0.001 for the fixed factor
time;*p < 0.05; **p < 0.01, ***p < 0.001 significant time ×meal interaction. In cases of significant interaction effects, p-values for single fixed factors are
not given.
3.6. Plasma oxLDL, Vitamin C, Retinol, 𝜶-Tocopherol,
𝜷-Carotene, and TEAC
Plasma oxLDL concentration was not affected by meal intake (p
= 0.121), time (p = 0.181), or the interaction of these (p = 0.442;
Figure 4F). Plasma vitamin C kinetic showed no time ×meal in-
teraction (p = 0.060), but a significant influence of the meal was
seen (p < 0.001) and a significant change over time (p < 0.001;
Figure 4A). After intake of the MED meal, vitamin C concentra-
tions rose to a maximum after 4 h, whereas vitamin C decreased
to a minimum at 3 h after WDHF and WDHC meal intake. To-
tal vitamin C response, shown by iAUC values, revealed signifi-
cantly higher iAUC values for the MED meal compared with the
remaining meals (p < 0.001).
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Table 3. Postprandial responses shown by incremental AUC (iAUC) for parameters of lipid and glucose metabolism, biomarkers of inflammation, and
antioxidant status in participants of high CVD risk.
MED WDHF WDHC p-value (meal effect)
Glucose iAUC [h mmol L−1] 4.3 ± 0.7a 3.2 ± 0.4a,b 5.2 ± 0.7b 0.002
Insulin iAUC [h pmol L−1] 1720 ± 155a 1426 ± 93 b 2167 ± 178a,b <0.001
GLP-1 iAUC [h pmol L−1] 44.9 ± 3.9 45.6 ± 3.9 44.2 ± 3.5 0.978
Triglyceride iAUC [h mmol L−1] 3.1 ± 0.2 a 4.0 ± 0.2 a,b 2.9 ± 0.2 b <0.001
NEFA iAUC [h mmol L−1] −1.3 ± 0.1 a −1.0 ± 0.1 a,b −1.5 ± 0.1 b <0.001
Total cholesterol iAUC [h mmol L−1] −0.14 ± 0.15 −0.46 ± 0.12 −0.26 ± 0.14 0.134
LDL iAUC [h mmol L−1] −0.46 ± 0.08 −0.53 ± 0.07 −0.38 ± 0.08 0.305
HDL iAUC [h mmol L−1] −0.25 ± 0.03 −0.33 ± 0.04 −0.22 ± 0.04 0.063
Inflammation
IL-1𝛽 iAUC [h pg mL−1] 0.01 ± 0.02 0.02 ± 0.02 0.02 ± 0.04 0.754
IL-6 iAUC [h pg mL−1] 17.3 ± 1.3 15.0 ± 0.9 16.4 ± 1.2 0.488
Adhesion molecules
sE-selectin iAUC [h ng mL−1] −2.7 ± 1.1 −5.5 ± 1.2 −5.8 ± 1.6 0.112
sICAM-1 iAUC [h ng mL−1] −15.1 ± 11.5 −29.9 ± 16.7 −13.6 ± 13.2 0.710
sVCAM-1 iAUC [h ng mL−1] −32.3 ± 53.1 −83.2 ± 35.4 −169.2 ± 61.0 0.227
Oxidation and antioxidant
OxLDL iAUC [h ng mL−1] 2.2 ± 9.2 9.5 ± 9.6 9.1 ± 10.9 0.809
Vitamin C iAUC [h mg L−1] 2.8 ± 0.8a,b −4.5 ± 0.6 a −3.5 ± 0.9b <0.001
Tocopherol iAUC [h 𝜇g mL−1] −2.2 ± 0.8 −1.4 ± 0.4 −1.0 ± 0.7 0.553
𝛽-Carotene iAUC [h ng mL−1] −38.9 ± 23.3 −44.3 ± 13.1 −36.1 ± 28.9 0.953
Retinol iAUC [h ng mL−1] −22.2 ± 21.0 −37.5 ± 17. 4 −10.3 ± 20.0 0.368
TEAC iAUC [h mmol trolox equivalent L−1] −0.10 ± 0.04 −0.15 ± 0.04 −0.15 ± 0.04 0.641
Values given as mean ± SEM. Means denoted with lowercase letters indicate statistical significance Post-hoc analyses (least significant difference; p < 0.05). Statistical
differences are given between values with the same lowercase letters a and b; MED,Mediterranean diet-like meal; IL-1𝛽, interleukin-1𝛽; IL-6, interleukin-6; NEFA, non-esterified
fatty acid; oxLDL, oxidized LDL; sE-selectin, soluble E-selectin; sICAM-1, soluble intercellular adhesion molecule-1; sVCAM-1, soluble vascular cell adhesion molecule-1; TEAC,
trolox equivalent capacity; WDHC, Western diet-like high-carbohydrate meal; WDHF, Western diet-like high-fat meal.
Plasma concentrations of 𝛼-tocopherol, retinol, and 𝛽-carotene
as well as TEAC showed no significant time × meal interaction
and did not differ between meals (Figure 4B–E). A significant re-
duction was seen over time for 𝛼-tocopherol (p < 0.001), retinol
(p < 0.001), 𝛽-carotene (p = 0.032), and TEAC (p < 0.001).
4. Discussion
In this randomized, controlled, postprandial study in over-
weight/obese individuals, all threemeal patterns induced signifi-
cant changes in glucose, insulin, GLP-1, triglycerides, NEFA, an-
tioxidant state and pro-inflammatory markers, when compared
with the fasted state. In accordance with our hypothesis, theMED
diet meal showed beneficial effects on glucose, insulin, triglyc-
erides, NEFA, and vitamin C responses compared to the West-
ern diet meals, as indicated by differences in time × meal in-
teractions. In addition, all meals resulted in similar increases
in GLP-1 and IL-6, and decreases in TEAC, tocopherol, retinol,
and 𝛽-carotene, with no significant differences between the three
meals. By contrast, no postprandial increases in soluble endothe-
lial adhesion molecule and oxLDL were seen. The unique aspect
of our work is that we focused on a clinically relevant population,
overweight and moderately obese older individuals with a clus-
ter of metabolic syndrome traits, and that we used a whole diet
approach to study acute effects of meals on a wide array of car-
diometabolic parameters.
All meals induced hyperglycemia and hyperinsulinemia
with higher and more prolonged increases being associated
with the WDHC meal than with the MED and WDHF meals.
These findings may be explained by the higher content of total
carbohydrates and mono- and disaccharides in the WDHC meal
than in the other two meals. In addition, the fiber content of
the MED meal was considerably higher than that of the WDHC
meal (14 vs 5 g per meal), which could partly account for the
lower glycemic and insulinemic response. Dietary fiber can
modify the gastrointestinal transit time, which, in turn, can alter
rates of glucose absorption thereby influencing blood glucose
homeostasis.[26] The results of the current study are consistent
with those from previous studies, where partial substitution of
high-glycemic load (GL) foods with foods of a lower GL, as well as
the modification of the macronutrient profile (e.g., combinations
of carbohydrates with fat and/or dietary fiber) led to a lower post-
prandial glucose response.[27–29] In addition, our results are in
line with a recent systematic review andmeta-analysis of Kdekian
et al.[30] showing that modest exchange of carbohydrates for fats
in mixed meals significantly reduces postprandial glucose and
insulin.
The high insulin response after all three meals caused a
rapid decline in postprandial glucose, with lower plasma glu-
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Figure 3. Fasting and postprandial concentration of plasma A) IL-1𝛽, B) IL-6, C) sE-selectin, D) sICAM-1, and E) sVCAM-1 in participants of high risk of
CVD. Data are presented asmeans± SEM. IL-1𝛽, interleukin-1𝛽; IL-6, interleukin-6;MED,Mediterranean diet-likemeal; sICAM-1, soluble intercellular ad-
hesion molecule 1; sVCAM-1, soluble vascular adhesion molecule 1; WDHF, Western diet-like high-fat meal; WDHC, Western diet-like high-carbohydrate
meal. No time ×meal interactions were observed on postprandial concentrations. ●●p < 0.01, ●●●p < 0.001 for the fixed factor time; ×p < 0.05 for the
fixed factor meal.
cose concentrations being observed 5 h postprandially than at
baseline (Figure 2) confirming previous results of our research
group.[23,31] To complement these findings, the increased GLP-
1 concentrations can serve to explain the increased glucose-
stimulated insulin secretion after all three meals. In that, the
slightly increased incretin and insulin concentrations are within
the physiological range of metabolic responses, which is unlikely
to affect the glucose tolerance of healthy humans. However, it re-
mains to be tested whether patients with type 2 diabetes would
respond differently.
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Figure 4. Fasting and postprandial concentrations of plasma A) vitamin C, B) tocopherol, C) retinol, and D) 𝛽-carotene, E) TEAC, and F) oxidized LDL in
participants of high risk of CVD. Data are presented as mean ± SEM. MED, Mediterranean diet-like meal; TEAC, trolox equivalent antioxidant capacity;
WDHF, Western diet-like high-fat meal; WDHC, Western diet-like high-carbohydrate meal. No time × meal interactions were observed for postprandial
concentrations. ●p < 0.05, ●●●p < 0.001 for the fixed factor time; ××p < 0.01 for the fixed factor meal.
All threemeals induced a postprandial increase in triglycerides
with higher concentrations seen at 2–4 h after the WDHF meal
than after the MED and WDHC meal. In addition, postpran-
dial NEFA responses differed, with significantly higher concen-
trations seen after the WDHF meal than the other meals (Fig-
ure 2). This stronger response may primarily result from the
higher total fat and SFA content of the WDHF meal. Postpran-
dial triglyceride concentrations are a significant independent risk
factor for CVD.[32,33] In normolipidemic adults, the magnitude
of the postprandial triglyceride response is directly dependent
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on the amount of fat ingested.[34] Less is known about the im-
portance of fatty acid composition and different fatty acid food
sources (e.g., SFA from meat vs SFA from butter) on postpran-
dial lipemia in individuals at risk of CVD. In our study, major
sources of SFA were butter and cold cuts of meat, and the major
SFA was palmitic acid. Some previous studies in healthy individ-
uals have shown that SFA (e.g., from butter, lard or coconut oil)
results in a lower[27,35–37] or similar[38] increase in triglycerides
than MUFA and/or PUFA. In contrast, other studies show that
ingestion of MUFA (e.g., from olive oil) in test meals induces
lower postprandial triglyceride concentrations than SFA (e.g.,
from butter or cheese) in healthy individuals,[39] in patients with
impaired fasting glucose[40] and in individuals with elevated fast-
ing triglycerides.[41] The main mechanisms underlying this ob-
servation are thought to include a higher MUFA clearance rate
than with SFA, as well as an enhanced incretin effect, followed
by slower gastric emptying. A recent review and meta-analysis
aimed at investigating and quantifying the effects of oral fat tol-
erance tests also showed lower triglyceride responses to unsatu-
rated fatty acids when compared to SFA.[42]
Reductions in postprandial NEFA concentrations were signif-
icantly more pronounced after the WDHC and MED meal than
after theWDHFmeal intake. This finding can be explained by the
higher levels of carbohydrates in the WDHC and MEDmeals. In
particular, the high amounts of mono- and disaccharides (87 g
per meal) in the WDHC meal results in higher glucose and con-
sequently higher insulin concentrations. Insulin activates LPL on
the endothelium of adipose tissue causing an increase in triglyc-
eride storage in the adipose tissue. Furthermore, insulin inhibits
triglyceride lipolysis, leading to a lower level of NEFA in the
blood.[43,44] This may explain the more pronounced decrease in
NEFA seen afterWDHCmeal intake. These observations are con-
sistent with those reported previously.[45,46]
Persistent low-grade inflammation is an important underly-
ing factor in the etiology of metabolic and vascular diseases.[10,47]
In the present study of older individuals at increased CVD risk,
plasma IL-6 increased by approximately 100% from baseline in
response to the three meals. Similar findings have been observed
in healthy individuals < 60 years of age after high-fat, high-
energy meals.[9] As it is assumed that postprandial glycemia and
lipemia induce a pro-oxidative state that triggers inflammation,[9]
the lack of difference in IL-6 response between the meals was
somewhat unexpected. The WDHC meal resulted in a higher
glycemic response, whereas the WDHF meal led to a higher
lipemic response than theMEDmeal. However, these differences
did not translate into distinct inflammatory responses. We there-
fore speculate that energy load is the main determinant for acute
postprandial inflammatory response but this cannot be actually
inferred from our study design because we administered isoen-
ergetic meals.
No postprandial IL-1𝛽 response was seen in any of the three
groups and previous data are scarce and equivocal.[9,48] The re-
sults of the current study are in agreement with data from a study
of patients with metabolic syndrome, which showed no increase
in plasma IL-1𝛽 after a high-fat challenge (3473 kJ).[48] In an-
other postprandial study using meals high in SFA in subjects
with metabolic syndrome, serum IL-1𝛽 fell below the detection
limit in most samples and consequently data could not be in-
cluded into the statistical analyses.[49]
Previous postprandial studies have demonstrated that meals
that are rich in fat and energy lead to a low-grade meal-induced
impairment of endothelial function measured by flow-mediated
dilatation and/or blood concentrations of endothelial adhesion
molecules.[7,50,51] In this context, the fatty acid profile, particu-
larly the amount of SFA, appears to be an important factor.[52,53]
Endothelial adhesion molecules such as VCAM-1, ICAM-1, and
E-selectin are pro-inflammatory proteins which play a critical
role in the adhesion of leukocytes to endothelial cells during
the early stages of atherosclerosis.[47] Their concentration is low
normal conditions, but they can increase when the endothe-
lium is activated by stimuli such as proinflammatory cytokines
and reactive oxygen species.[8,47] In the present study, the pro-
nounced lipemic, glycemic, insulinemic, and inflammatory
responses induced by all three meals did not lead to increased
endothelial activation. In fact, the biomarkers of endothelial
activation sVCAM-1 and sE-selectin decreased over time. This
finding supports data generated in two recent trials of CVD
risk individuals.[23,31] The slight decrease in biomarkers of
endothelial activation over time may be attributable to circadian
variability.[54,55]
Oxidative stress naturally occurs during the postprandial pe-
riod and oxLDL has been identified as an oxidative marker
with high atherogenic potential.[56,57] In contrast to previous
studies,[31,58] plasma oxLDL did not increase during the postpran-
dial period (Figure 4), although the energy content of the meals
was comparable to previous studies. On the other hand, the ob-
served decrease in TEAC and plasma antioxidants is inconsistent
with the hypothesis that high-energy challenges increase post-
prandial oxidative stress. The postprandial plasma concentration
of vitamin C was higher after the MED meal compared to the
WDHF and WDHC meals, which is consistent with the higher
vitamin C content of this test meal. In general, the effect of meal
ingestion on biomarkers of oxidative stress is a contentious issue,
which might, at least in part, be explained by the lack of sensitive
techniques suitable to quantify low-grade oxidative stress in hu-
man intervention studies.[59]
The strengths of this study include the randomized, controlled,
crossover study design, the assessment of a broad range of car-
diometabolic risk indicators, the relatively large sample size and
the inclusion of participants with a cluster of metabolic syn-
drome traits, who are likely to have more pronounced postpran-
dial reactions.[8,11] In addition, the meals were designed to meet
the food and nutrient characteristics of the Mediterranean and
the Western dietary patterns.[3,60,61] Trials that apply isolated nu-
trient challenges are not likely to identify the entire range of
metabolic stimuli. One limitation of the present study is the
5 h postprandial period, which may not have been sufficient for
some of the study variables to peak (e.g., IL-6) and/or return to
baseline concentrations (e.g., triglycerides). Therefore, the dif-
ference between the three meals after the 5 h postprandial pe-
riod is not known. Particularly in terms of parameters of glucose
metabolism, it might have been relevant to include postprandial
time points at 30 min and 15 min in order to evaluate possible
meal effects on the early postprandial rise in plasma glucose and
serum insulin. In addition, as this study only recruited older Eu-
ropeanmen and women with a CVD risk phenotype it is possible
that the results may differ in other populations (e.g., metaboli-
cally healthy participants).
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In conclusion, in this population of older adults with a risk
phenotype for cardiometabolic diseases, intake of an energy rich
meal resulted in hyperglycemia, hyperlipemia, an inflammatory
response, and a decrease in antioxidant markers. A meal typ-
ical of the Mediterranean diet resulted in favorable effects on
glycemic, insulinemic, and lipemic responses compared with
meals typical of Western dietary patterns. As the inflammatory
response was present to the same degree after eachmeal, we sug-
gest that energy intake is the main predictor of postprandial in-
flammation.
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